‘Enabling Future Pharma – Beyond the Pill’, is developing a suite of innovative and agile programmes aimed to create a skilled talent pool focused on emerging and future pharma technologies, addressing skills gaps in industry and enabling future growth. Specifically, RCSI and its partners are developing a MSc in Precision Medicine and Innovation and a BSc in advanced therapeutic technologies. These two programmes will be delivered using cutting edge educational technology to maximise flexible delivery. Learning outcomes will focus on technological knowledge and skills, in combination with transversal skills.

In order to develop and implement these programmes, RCSI requires access to software that enables students in the diagnostic interpretation of whole genome and exome next-generation sequence data. In addition, we require industry-informed teaching in specific areas related to the clinical application of genomics.

‘Enabling Future Pharma – Beyond the Pill’, is developing a suite of innovative and agile programmes aimed to create a skilled talent pool focused on emerging and future pharma technologies, addressing skills gaps in industry and enabling future growth. Specifically, RCSI and its partners are developing a MSc in Precision Medicine and Innovation and a BSc in advanced therapeutic technologies. These two programmes will be delivered using cutting edge educational technology to maximise flexible delivery. Learning outcomes will focus on technological knowledge and skills, in combination with transversal skills.

In order to develop and implement these programmes, RCSI requires access to software that enables students in the diagnostic interpretation of whole genome and exome next-generation sequence data. In addition, we require industry-informed teaching in specific areas related to the clinical application of genomics.